US 12,168,027 B2
Methods associated with tumor burden for assessing response to a cell therapy
Tina Albertson, Seattle, WA (US); Jacob Randolph Garcia, Seattle, WA (US); and He Li, Seattle, WA (US)
Assigned to Juno Therapeutics, Inc., Seattle, WA (US)
Filed by Juno Therapeutics, Inc., Seattle, WA (US)
Filed on Dec. 16, 2022, as Appl. No. 18/067,672.
Application 18/067,672 is a continuation of application No. 16/760,382, granted, now 11,564,946, previously published as PCT/US2018/058579, filed on Oct. 31, 2018.
Claims priority of provisional application 62/580,417, filed on Nov. 1, 2017.
Prior Publication US 2023/0172988 A1, Jun. 8, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/17 (2015.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); G01N 33/574 (2006.01)
CPC A61K 35/17 (2013.01) [A61P 35/00 (2018.01); C07K 16/2803 (2013.01); G01N 33/57407 (2013.01)] 37 Claims
 
1. A method of reducing the risk of development of a toxicity in a subject, the method comprising:
(a) measuring a sum of products of diameters (SPD) of a tumor of a subject having a cancer at a first time point and a second time point that are each measured prior to administration of a T cell therapy for treatment of a cancer, wherein the subject is a candidate for receiving the T cell therapy, and wherein the fold change of the SPD of the tumor between the first time point and the second time point is about 5 or greater; and
(b) administering to the subject: (i) the T cell therapy, and (ii) an agent capable of reducing the risk of development of a toxicity, wherein the toxicity is cytokine release syndrome (CRS) or neurotoxicity.